Findings

What do systematic reviews say?

14 questions · 14 findings · 3 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 12 · 85.7%Very low 0 · 0%Low 0 · 0%Moderate 2 · 14.3%High 0 · 0%

Sucralfate vs placebo or usual care

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.98 [0.88, 1.1]
3 studies · 222 participants
Moderate

Sucralfate vs placebo or usual care

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Sucralfate probably leads to lower oral mucositis (severe) compared with placebo/usual care (moderate certainty).

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.67 [0.48, 0.92]
7 studies · 428 participants
Moderate

Sucralfate vs placebo or usual care

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Sucralfate showed no clear difference in oral mucositis (moderate to severe) compared with placebo/usual care; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.75 [0.54, 1.04]
4 studies
GRADE not reported

Sucralfate vs placebo

Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Sucralfate showed no clear difference in mucositis eradicated compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 1.13 [0.66, 1.94]
2 studies · 84 participants
GRADE not reported

Sucralfate vs placebo

Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Sucralfate showed no clear difference in improvement in mucositis compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.93 [0.71, 1.24]
1 study · 34 participants
GRADE not reported

Sucralfate vs Salt and soda mouthwash

Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Sucralfate showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD 13.10 [-6.30, 32.50]
1 study · 28 participants
GRADE not reported

Sucralfate vs Salt and soda mouthwash

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Sucralfate showed no clear difference in average pain scores (0-100 VAS) compared with salt and soda mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -0.30 [-1.03, 0.43]
1 study · 29 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Interruptions to cancer treatment · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in interruptions to cancer treatment compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.13 [0.01, 2.36]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.18 [0.01, 3.56]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Oral mucositis (severe) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (severe) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.54 [0.24, 1.21]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Oral mucositis (moderate to severe) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.96 [0.80, 1.14]
1 study · 40 participants
GRADE not reported

GM-CSF vs sucralfate

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

GM-CSF showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.96 [0.8, 1.14]
1 study · 40 participants
GRADE not reported

GM-CSF vs sucralfate

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

GM-CSF showed no clear difference in oral mucositis (severe) compared with sucralfate; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.54 [0.24, 1.21]
1 study · 40 participants
GRADE not reported

Gelclair vs Sucralfate and mucaine

Mucositis severity (mild to moderate) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Gelclair showed no clear difference in mucositis severity (mild to moderate) compared with sucralfate and mucaine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.50 [0.17, 1.46]
1 study · 20 participants
GRADE not reported